EPAM Systems Inc vs State Street SPDR S&P Biotech ETF — how do they compare? EPAM Systems Inc trades at $99.88 (market cap $5.15B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| EPAM | XBI | |
|---|---|---|
Market Cap | $5.15B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $221.40 | $164.28 |
52-Week Low | $76.04 | $86.92 |
Enterprise Value | $4.52B | — |
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $100.29, up 3.0% with recent earnings beats but faces technical bearish signals. The company reported strong Q2 2026 results with EPS of $3.38 beating estimates, though revenue guidance was lowered due to North American softness. Valuation appears attractive with P/E of 13.55 and P/S of 0.97, while profitability metrics remain solid with 7.15% net margin.
The stock presents a value opportunity with analyst consensus target of $117.27 (17% upside), but faces near-term headwinds from reduced revenue guidance and technical weakness. Key risks include slowing demand in core markets, while the OpenAI partnership offers AI growth potential. Institutional sentiment remains positive with 65% buy ratings.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Trailing returns across standard periods
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →